Written by the Nuvirox Research Team
Key points
- The idea that NAD+ falls with age is widely repeated, but the human tissue evidence is surprisingly limited and mixed — far less settled than marketing implies.
- Preclinical (animal) data more consistently show decline; translating that to humans is where the picture gets murky.
- Raising NAD+ with precursors in humans is well established; whether that reverses an age-related deficit, or improves health outcomes, is a separate and less certain question.
Short answer: "NAD+ declines with age" is true in animal models and plausible in humans, but the actual human tissue evidence is thinner and more mixed than the supplement marketing suggests. It’s a reasonable working hypothesis, not a settled fact — and being honest about that distinction is more useful than repeating a tidy story.
What is NAD+ and why would it decline?
NAD+ (nicotinamide adenine dinucleotide) is a cofactor your cells can’t function without. Beyond its classic role carrying electrons in energy production, it’s consumed by enzymes involved in DNA repair, stress responses, and cellular signaling. The decline hypothesis runs like this: with age, NAD+-consuming demands rise (more DNA damage to repair, more inflammatory signaling) while synthesis may not keep pace, lowering net availability. It’s a coherent mechanism — and it’s why NAD+ became a longevity and mitochondrial talking point.
What human studies actually show
The animal data are more consistent than the human data. Preclinical studies have repeatedly reported NAD+ decline with aging, but researchers themselves note that human tissue data are sparse. This gap is the crux of the whole question.
One striking human finding cuts against the simple story. In the course of the Elhassan study, magnetic resonance spectroscopy measurement of NAD+ in muscle and brain showed no significant difference between young and aged individuals (Elhassan 2019). That’s a direct human measurement that didn’t find the expected age gap — a reminder that the tissue picture is unsettled.
Raising NAD+ in humans, by contrast, is well established. Nicotinamide riboside at 1,000 mg/day reliably increased NAD+ in healthy middle-aged and older adults (Martens 2018), and nicotinamide mononucleotide raised blood NAD+ in older men with nominal functional signals (Igarashi 2022). So we can move the number up; whether we’re correcting a deficit is the harder claim. We treat the do-supplements-raise-NAD question separately here.
Study snapshot — the human age-gap check
Source: Elhassan 2019 (Cell Reports)
Method: 31P-MRS NAD+ measurement in muscle and brain
Comparison: Young vs. aged individuals
Finding: No significant young-vs-aged difference in measured tissue NAD+
Why the honest answer matters
A lot of supplement copy presents age-related NAD+ decline as established fact and then positions a product as the fix. The more accurate position is layered: decline is well supported in animals, plausible but not firmly demonstrated in human tissue, and the act of raising NAD+ in people is real but its translation into clear health outcomes remains an active research question. If a brand skips those caveats, that tells you something about the brand.
What this means if you're considering a precursor
It’s reasonable to view an NAD+ precursor as cellular-energy support with a plausible mechanism and a reliable biomarker effect — not as a proven antidote to aging. Doses in human trials have ranged widely (often 250–1,000 mg/day and higher), and the precursor is generally well tolerated. Set expectations to match the evidence, give any trial a fair time window, and keep the foundational basics — sleep, movement, food — doing the bulk of the work.
Frequently asked questions
Does NAD+ definitely decline as we age?
In animal models, fairly consistently. In human tissue, the evidence is limited and mixed — one human measurement found no significant young-vs-aged difference in muscle and brain. It’s a plausible hypothesis, not a settled fact.
Can supplements raise NAD+ in people?
Yes — this part is well established. Nicotinamide riboside and NMN both reliably raise blood NAD+ in human trials. Whether that corrects an age-related deficit or improves outcomes is the less-certain question.
If NAD+ decline isn't proven, are precursors pointless?
Not necessarily. NAD+ is essential biology and precursors reliably raise it. The honest framing is cellular-energy support with a plausible mechanism — not a proven anti-aging fix. Match your expectations to that.
How much NAD+ precursor do trials use?
Human studies have used a range, commonly 250–1,000 mg/day and sometimes higher, generally with good tolerability. There’s no single established optimal dose for healthy adults.
Why measuring tissue NAD+ is so hard
Part of why the human picture stays unsettled is simply that NAD+ is difficult to measure where it matters. Blood NAD+ is accessible and moves reliably with supplementation — which is why nearly every trial reports it — but blood isn’t the same as muscle, brain, or other tissues, and the relationship between them isn’t one-to-one. Direct tissue measurement requires biopsies or specialized imaging, which is exactly why human tissue datasets are small and sometimes conflicting.
This is the gap that marketing tends to paper over. "Blood NAD+ went up" is well established; "tissue NAD+ was low and we corrected it" is a much harder claim to support in humans, and one direct imaging comparison found no significant young-versus-aged difference at all. The realistic takeaway is to value what’s measured — a reliable rise in the biomarker — without over-reading it. Our do-NAD-supplements-raise-NAD and mitochondria-and-NAD pieces stay within those honest bounds.
From Nuvirox
Why we formulated NAD+ Restore
We formulated NAD+ Restore around the part that’s actually well supported: delivering a researched NAD+ precursor, NR, at a meaningful dose to support cellular energy metabolism. We don’t claim it reverses aging — the evidence doesn’t, and we’d rather you trust the honest version.
Each two-capsule serving provides 500 mg of nicotinamide riboside chloride (NR) — one of the two most-researched NAD+ precursors, within the dose range used in published human trials. We pair it with 150 mg trans-resveratrol (from Japanese Knotweed) and 50 mg quercetin (from Sophora japonica), polyphenols studied alongside NAD+ pathways for cellular health support, plus 10 mg galactomannans from fenugreek to support absorption.
It comes with a 60-day money-back guarantee — long enough to actually evaluate it the way the research says you should.
Learn more about NAD+ Restore →The bottom line
NAD+ decline with age is well supported in animals, plausible but unsettled in human tissue, and sometimes contradicted by direct human measurement. What’s solid is that precursors raise NAD+ in people; what’s uncertain is whether that fixes an age-related deficit or delivers clear outcomes. Treat an NAD+ precursor as evidence-based cellular energy support with honest limits — not a settled cure for getting older.
References
- Elhassan YS, et al. Nicotinamide riboside augments the aged human skeletal muscle NAD+ metabolome and induces transcriptomic and anti-inflammatory signatures. Cell Reports. 2019;28(7):1717-1728. doi:10.1016/j.celrep.2019.07.043. PMID: 31412242.
- Martens CR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications. 2018;9:1286. doi:10.1038/s41467-018-03421-7. PMID: 29599478.
- Igarashi M, et al. Chronic nicotinamide mononucleotide supplementation elevates blood NAD+ levels and alters muscle function in healthy older men. npj Aging. 2022;8:5. doi:10.1038/s41514-022-00084-z. PMID: 35927255.
- McDermott MM, et al. Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial. Nature Communications. 2024;15:5046. doi:10.1038/s41467-024-49092-5. PMID: 39112480.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.